Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.2525
-0.0195 (-7.17%)
At close: Aug 28, 2026, 4:00 PM EDT
0.2575
+0.0050 (1.98%)
After-hours: Aug 28, 2026, 7:52 PM EDT
Mereo BioPharma Group Employees
Mereo BioPharma Group had 39 employees as of December 31, 2025. The number of employees increased by 3 or 8.33% compared to the previous year.
Employees
39
Change (1Y)
3
Growth (1Y)
8.33%
Revenue / Employee
n/a
Profits / Employee
-$720,487
Market Cap
40.32M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 39 | 3 | 8.33% |
| Dec 31, 2024 | 36 | 3 | 9.09% |
| Dec 31, 2023 | 33 | -3 | -8.33% |
| Dec 31, 2022 | 36 | -13 | -26.53% |
| Dec 31, 2021 | 49 | 11 | 28.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Metagenomi Therapeutics | 113 |
| Aligos Therapeutics | 82 |
| Filana Therapeutics | 20 |
| Veru Inc. | 20 |
| Tevogen | 18 |
| CervoMed | 15 |
| Werewolf Therapeutics | 14 |
MREO News
- 10 days ago - JPMorgan Downgrades Mereo BioPharma (MREO) Amid Regulatory Concerns, Highlighting Valuation and ... - GuruFocus
- 10 days ago - JPMorgan downgrades Mereo to Underweight on regulatory uncertainty - TheFly
- 11 days ago - Mereo BioPharma downgraded to Underweight from Neutral at JPMorgan - TheFly
- 18 days ago - Mereo BioPharma Advances Alvelestat Partnership; Cash Runway Extended Into Late 2027 - Nasdaq
- 18 days ago - Mereo BioPharma Group Releases Q2 2026 Financial Results - AlphaStreet
- 18 days ago - Mereo BioPharma (MREO) Advances Alvelestat Program, Faces Valuation Challenges - GuruFocus
- 18 days ago - Mereo BioPharma (MREO) Licenses Alvelestat Rights to Sentynl Therapeutics Amid High Valuation ... - GuruFocus
- 18 days ago - Mereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics - Nasdaq